Medcap reported a better Q2 versus our estimates, attributable to a strong performance in the Medtech segment with Abilia showing a robust recovery in Norway. We make small revisions to our estimates, raising our expectations for Medtech but lowering the outlook for speciality pharma, which is still facing challenges related to the CDMO offering. We adjust our DCF-based value range to SEK 201-232 (198-228) per share. Marketing material commissioned by MedCap.

equityresearch@nordea.com

Nordea Research